International Journal of Gynecological Cancer最新文献

{"title":"Practical strategies for environmentally sustainable practices in gynecologic oncology.","authors":"Ilker Kahramanoglu, Joanna Kacperczyk-Bartnik, Remi Nout, Francois Planchamp, Jacek Sienko, Kari Tanderup, Diana Zach, Frédéric Amant","doi":"10.1016/j.ijgc.2025.102648","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102648","url":null,"abstract":"<p><p>Sustainability in health care is an increasingly urgent priority, and gynecologic oncology (as a resource-intensive surgical specialty) offers opportunities to reduce environmental impact without compromising patient care. This review provides actionable, evidence-based strategies that individual clinicians, departments, and institutions can readily implement into routine practice. Practical anesthetic strategies, such as total intravenous anesthesia, regional anesthesia, and low-flow techniques, substantially decrease greenhouse gas emissions. Transitioning from disposable to reusable surgical instruments, drapes, and gowns significantly curbs waste. Energy-efficient solutions in the operating room, including optimized heating, ventilation, air conditioning systems, as well as light emitting diode lighting, minimize unnecessary energy use. Optimizing diagnostic imaging through clinical justification and powering down equipment when feasible further decreases energy consumption. Pharmaceutical-related strategies, including accurate chemotherapy dosing, safe medication disposal through drug take-back programs, and environmentally conscious procurement, mitigate harmful emissions and pharmaceutical waste. Surgical techniques such as sentinel lymph node biopsy, rather than extensive lymphadenectomy, also support sustainability goals by reducing resource consumption and procedural waste. Digital innovations, notably telemedicine, demonstrate clear environmental advantages by minimizing patient travel, particularly for routine follow-up and the collection of patient-reported outcomes. Enhanced Recovery After Surgery protocols, promoting shorter hospital stays and digital preoperative assessments, represent additional avenues for improvement. Preventive interventions, such as human papillomavirus vaccination programs and early cancer screening, are vital long-term sustainability investments, reducing resource-intensive treatments associated with advanced disease. By highlighting practical examples from recent studies and clinical experience, this review aims to encourage widespread adoption of sustainable practices in gynecologic oncology, aligning clinical excellence with global environmental goals.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102648"},"PeriodicalIF":4.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).","authors":"Corrado Terranova, Vanda Salutari, Francesco Plotti, Caterina Ricci, Anna Fagotti, Francesco Raspagliesi, Violante Di Donato, Paolo Scollo, Sunil Gupta, Jada Srinivasa Rao, Giovanni Scambia, Roberto Angioli","doi":"10.1016/j.ijgc.2025.102649","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102649","url":null,"abstract":"<p><strong>Objective: </strong>Oregovomab is a murine monoclonal antibody directed to the tumor-associated antigen CA125 that stimulates host cellular and humoral immune response against tumor cells expressing CA125. A single-arm phase II study in; treatment of patients with epithelial ovarian cancer, simultaneous day infusion of; oregovomab with paclitaxel and carboplatin dramatically enhanced the magnitude of; induced immunity relative to a 1-week delayed schedule and other schedules; historically evaluated. This randomized phase II study tested the hypothesis that; schedule-dependent chemotherapy with oregovomab may improve progression-free survival in optimally resected, stage III/IV ovarian cancer.</p><p><strong>Methods: </strong>Stage III/IV epithelial ovarian cancer patients optimally debulked to <1 cm residual disease with CA125 >50 U/mL were randomized to carboplatin-paclitaxel + oregovomab; cycle 1,3,5,C5 +12 weeks versus carboplatin-paclitaxel and followed for clinical outcomes and immune response. Secondary endpoints were clinical evaluations and safety.</p><p><strong>Results: </strong>A total of 97 patients were randomized to the protocol, 47 to carboplatin-paclitaxel-oregovomab and 50 to carboplatin-paclitaxel. Progression-free survival analysis revealed a median progression-free survival of 41.8 months (95% CI 21.8-not estimable [NE]) for carboplatin-paclitaxel-oregovomab and 12.2 months (10.4-18.6) for carboplatin-paclitaxel (HR 0.46, CI 0.28 to 0.7, p = .0027). An updated long-term overall survival analysis was performed with a median follow-up of 109.4 months which demonstrated that in the intent-to treat population the median overall survival for carboplatin-paclitaxel-oregovomab was 121.3 months (95% CI 106.2 to NE) and 64.7 months (95% CI 38.2 to NE) for carboplatin-paclitaxel (HR 0.47, 95% CI 0.26 to 0.86, p = .0116).</p><p><strong>Conclusions: </strong>This study suggests that simultaneous administration of oregovomab on alternate cycles during front-line carboplatin and paclitaxel could enhance progression-free survival and long-term overall survival. This increase in median overall survival after 9 years of follow-up is meaningful in patients with optimally debulked epithelial ovarian cancer.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102649"},"PeriodicalIF":4.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining surgical goals: beyond R0 for long-term survival in advanced ovarian cancer.","authors":"Fatma Ferda Verit","doi":"10.1016/j.ijgc.2025.102652","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102652","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102652"},"PeriodicalIF":4.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term oral contraceptive use as a risk factor for high-grade cervical lesions in women with high-risk human papillomavirus: a retrospective cohort analysis.","authors":"Farah Farzaneh, Fatemeh Dastyar, Marzieh Mohammadi, Maryam Sadat Hosseini, Amir Soltani","doi":"10.1016/j.ijgc.2025.102650","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102650","url":null,"abstract":"<p><strong>Objective: </strong>While high-risk human papillomavirus (HPV) is the established cause of cervical intraepithelial neoplasia (CIN), cofactors influencing progression to high-grade disease remain poorly defined. This study aimed to investigate the association between long-term oral contraceptive use and the risk of high-grade CIN (grade 2/3) in a high-risk referral population.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the records of 684 women screened at a specialized gynecologic oncology clinic (2019-2024). Data on oral contraceptive use (≥5 years), high-risk HPV status, age, and smoking history were extracted. The primary outcome was CIN grade. To mitigate bias from sparse data, Firth-penalized logistic regression was used to calculate adjusted ORs (aOR) for the association between long-term oral contraceptive use and CIN grade.</p><p><strong>Results: </strong>Long-term oral contraceptive use was reported by 5.6% of the cohort. After adjusting for confounders, long-term oral contraceptive use was strongly associated with a 16.8-fold increased odds of high-grade CIN (aOR 16.79, 95% CI 3.82 to 73.70, p < .001). However, the wide CI indicates significant statistical uncertainty in the magnitude of the effect. Conversely, oral contraceptive use was associated with significantly lower odds of low-grade CIN (aOR 0.04, 95% CI 0.01 to 0.15, p < .001).</p><p><strong>Conclusions: </strong>In this high-risk population, long-term oral contraceptive use is a significant independent risk factor for high-grade cervical lesions, while paradoxically being associated with a lower risk of low-grade disease. This suggests an important role for hormonal factors in the progression of cervical neoplasia. Clinicians should consider long-term oral contraceptive use a key risk indicator in HPV-positive women and incorporate this modifiable factor into patient counseling.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102650"},"PeriodicalIF":4.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychophysical and social impact of risk-reducing salpingo-oophorectomy in China: a cross-sectional study.","authors":"Xinyu Ha, Zheng Feng, Jing Xia, Ziqi Liu, Jiajia Wang, Zuo Ke, Yu Lin, Yaqiong Chen, Hao Wen, Xiaohua Wu","doi":"10.1016/j.ijgc.2025.102135","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102135","url":null,"abstract":"<p><strong>Objective: </strong>Risk-reducing salpingo-oophorectomy has been adopted in China as an effective preventive measure against ovarian cancer, particularly for individuals with breast cancer gene (BRCA) mutations. While the procedure's efficacy in reducing ovarian cancer risk is well established, the associated psychophysical and social impacts have received limited attention. Understanding these impacts is critical for enhancing patient care and improving quality of life.</p><p><strong>Methods: </strong>This retrospective study included 154 BRCA mutation carriers who underwent risk-reducing salpingo-oophorectomy at Fudan University Shanghai Cancer Center between October 2016 and March 2024. A total of 136 patients were successfully followed up for quality-of-life assessment. Data were collected using the Self-Rating Anxiety Scale, Menopause Rating Scale, Decision Regret Scale, Decision Conflict Scale, and self-reported evaluations. Descriptive statistics were employed to summarize the data, and subgroup analyses were conducted to identify potential influencing factors.</p><p><strong>Results: </strong>The median age of participants was 46 years. Personal histories of breast cancer were reported in 63.97% (87/136) of the patients, and 8.82% (12/136) were diagnosed with occult ovarian cancer or precancerous lesions post-surgery. Among the cohort, 71.32% (97/136) were postmenopausal. Of the premenopausal patients, only 6 attempted hormone replacement therapy. Anxiety levels and menopausal symptoms were not significantly associated with clinical or demographic variables. Most patients reported low decision regret, with 89.71% (122/136) expressing complete satisfaction with the surgery and only 5.88% (8/136) reporting persistent stress. However, sexual dysfunction was reported by 46.32% (63/136).</p><p><strong>Conclusion: </strong>Risk-reducing salpingo-oophorectomy is associated with significant challenges, particularly concerning sexual dysfunction. These findings underscore the need for comprehensive preoperative counseling that distinctly addresses biomedical, physiological, and psychosocial considerations, alongside postoperative support to manage the quality-of-life impacts of risk-reducing salpingo-oophorectomy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102135"},"PeriodicalIF":4.7,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermediate-risk endometrial carcinoma: is the evidence ripe for this strength of recommendation?","authors":"Francesco Olivero, Anna Maria Merlotti, Stefania Martini, Paola Critelli, Jacopo Di Muzio","doi":"10.1016/j.ijgc.2025.102132","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102132","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102132"},"PeriodicalIF":4.7,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery plus post-operative radiotherapy versus definitive chemoradiotherapy in locally advanced endocervical adenocarcinoma.","authors":"Jong Yun Baek, Won Park, Won Kyung Cho, Hyun-Soo Kim, Byoung-Gie Kim, Jeong-Won Lee, Chel Hun Choi, Tae-Joong Kim, Yoo-Young Lee","doi":"10.1016/j.ijgc.2025.102013","DOIUrl":"10.1016/j.ijgc.2025.102013","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated whether treatment outcomes for endocervical adenocarcinoma differ according to treatment modality (surgery plus post-operative radiotherapy versus definitive chemoradiotherapy) and human papillomavirus (HPV) status.</p><p><strong>Methods: </strong>We retrospectively analyzed 105 patients with clinical stage IIB to IIIC endocervical adenocarcinoma, classified according to the 2018 International Federation of Gynecology and Obstetrics staging system, who were treated with surgery plus post-operative radiotherapy or definitive chemoradiotherapy at a single institution between 2011 and 2022. HPV status was determined based on the 2020 World Health Organization classification. Among the 105 patients, 61 had HPV-associated tumors and 44 had HPV-independent tumors. Patients were categorized into 4 groups: HPV-associated surgery plus post-operative radiotherapy (n = 46), HPV-associated definitive chemoradiotherapy (n = 15), HPV-independent surgery plus post-operative radiotherapy (n = 27), and HPV-independent definitive chemoradiotherapy (n = 17). Progression-free survival, locoregional recurrence-free survival, and overall survival were evaluated.</p><p><strong>Results: </strong>Baseline characteristics differed significantly among the 4 groups, particularly in clinical stage, tumor size, and parametrial invasion. The 3-year progression-free, locoregional recurrence-free, and overall survival rates were 47.4%, 54.7%, and 69.8%, respectively. By group, survival rates were 55.4%, 66.4%, and 76.9% for HPV-associated surgery plus post-operative radiotherapy; 52.5%, 52.5%, and 93.3% for HPV-associated definitive chemoradiotherapy; and 54.3%, 56.8%, and 67.5% for HPV-independent surgery plus post-operative radiotherapy, compared with significantly poorer rates of 11.8%, 20.6%, and 33.1% for HPV-independent definitive chemoradiotherapy (p < .05). These differences remained significant after multivariate adjustment, while no significant survival differences were observed between other groups. In a sub-group analysis of HPV-independent patients with clinical T2 to T3 disease, definitive chemoradiotherapy remained associated with worse outcomes than surgery plus post-operative radiotherapy.</p><p><strong>Conclusions: </strong>Definitive chemoradiotherapy showed outcomes comparable to surgery plus post-operative radiotherapy in HPV-associated adenocarcinoma, but was associated with significantly worse survival in HPV-independent cases. Further studies are warranted to confirm these findings.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 9","pages":"102013"},"PeriodicalIF":4.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.","authors":"Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, Domenica Lorusso, Helen MacKay, Isabelle Ray-Coquard, Ana Oaknin, Antonio Gonzalez-Martin, Kosei Hasegawa, Bradley R Corr, Xiaohua Wu, Alexandra Leary, Tianle Hu, Lea Dutta, Chinyere E Okpara, Jodi McKenzie, Vicky Makker","doi":"10.1016/j.ijgc.2025.101812","DOIUrl":"10.1016/j.ijgc.2025.101812","url":null,"abstract":"<p><strong>Background: </strong>Randomized controlled trial data for patients with endometrial cancer who experience disease progression after anti-programmed cell death [ligand] 1 (PD-[L]1) therapy are lacking. E7386, a novel small-molecule inhibitor, has been shown to enhance anti-angiogenesis when combined with lenvatinib. The escalation and expansion parts of Study 102 showed preliminary anti-tumor activity and manageable safety of E7386 plus lenvatinib in patients with advanced, un-resectable, or recurrent endometrial cancer previously treated with anti-PD-(L)1.</p><p><strong>Primary objective: </strong>This study aimed to determine the optimal dose of E7386 in combination with lenvatinib.</p><p><strong>Study hypothesis: </strong>E7386 plus lenvatinib will show a manageable safety profile and clinically meaningful anti-tumor activity in patients with advanced, un-resectable, or recurrent endometrial carcinoma previously treated with chemotherapy and anti-PD-(L)1 therapy.</p><p><strong>Trial design: </strong>Study 102 is an open-label, global, phase 1b/2 trial. Patients with endometrial carcinoma will be randomized 1:1:1:1 to E7386 120 mg twice daily plus lenvatinib 14 mg once daily, E7386 60 mg twice daily plus lenvatinib 14 mg once daily, lenvatinib 24 mg once daily monotherapy, or treatment of physician's choice (doxorubicin 60 mg/m² once every 3 weeks or paclitaxel 80 mg/m² once weekly [3 weeks on/1 week off]).</p><p><strong>Major inclusion/exclusion criteria: </strong>Eligible patients are aged ≥18 years with Eastern Cooperative Oncology Group performance status of 0 to 1 and must have advanced, un-resectable, or recurrent endometrial carcinoma that has progressed on/after prior platinum-based chemotherapy and PD-(L)1-directed therapy. Up to 3 previous lines of therapy are permitted. Individuals with prior treatment with lenvatinib or E7386 or known intolerance and/or known hypersensitivity to E7386, lenvatinib, doxorubicin, or paclitaxel, or any of their excipients, are not eligible to participate.</p><p><strong>Primary end points: </strong>The primary end points are safety and the objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by investigator assessment at week 24.</p><p><strong>Sample size: </strong>The study aims to include 120 patients across approximately 80 investigational sites in North America, Europe, and Asia-Pacific regions. Estimated Dates for Completing Accrual and Presenting Results: Enrollment is expected to take approximately 9 months, with presentation of results in 2026.</p><p><strong>Trial registration: </strong>The trial is registered at ClinicalTrials.gov, NCT04008797.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101812"},"PeriodicalIF":4.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644].","authors":"Andreas Obermair, Val Gebski, Jeffrey Goh, Anna Kuchel, Alison Brand, Blossom Mak, Orla McNally, Eva Baxter, Thomas Jobling, Linda Mileshkin","doi":"10.1016/j.ijgc.2025.101961","DOIUrl":"10.1016/j.ijgc.2025.101961","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101961"},"PeriodicalIF":4.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prognosis model for PARP inhibitor therapies based on multiple genomic alterations associated with homologous recombination deficiency in ovarian cancer.","authors":"Tong Shu, Fan Yang, Lin Gao, Jinhua Zhou, Chao Zhang, Youguo Chen, Hong Zheng, Jundong Li","doi":"10.1016/j.ijgc.2025.101987","DOIUrl":"10.1016/j.ijgc.2025.101987","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop a high-performance prognostic model to predict poly(ADP-ribose) polymerase inhibitor (PARPi) treatment outcomes in patients with ovarian cancer.</p><p><strong>Methods: </strong>This was a retrospective cohort study. Inclusion criteria were high-grade serous or endometroid carcinoma, clear cell carcinoma with platinum-sensitive disease (>6 months without progression from the end of platinum) or platinum-responsive disease eligible for front-line PARPi therapy. All collected samples underwent OncoWES-HRD analysis, with an Homologous recombination deficiency (HRD) score threshold set at 39. We performed LASSO regression analysis to develop a predictive model for assessing the effectiveness of PARPi treatment in patients with ovarian cancer. The data were analyzed using R software.</p><p><strong>Results: </strong>We collected primary tumors from 221 Chinese patients with ovarian cancer, of whom 99 patients with high-grade serous ovarian carcinoma received PARPi treatment. Based on the HRD score threshold, 144 patients were classified as HRD-positive and 77 as HRD-negative. We found that the HRD-positive group had higher mutation frequencies of ANKHD1 and MUC16 compared to the HRD-negative group. Furthermore, biomarkers such as clonal mutations, BRCA mutations, high indel burden, and high loss-of-heterozygosity were associated with notably higher HRD scores and longer progression-free survival. Using HRD genomic features, we established a LASSO regression-based risk score model for predicting PARPi treatment outcomes. This model showed promising performance compared to other HRD assessments (the OncoWES-HRD score and the OncoWES-HRD and BRCA metrics), with a higher area under the curve and significantly longer progression-free survival (p< .05) in both training and test cohorts.</p><p><strong>Conclusions: </strong>We developed a novel prognostic model that can predict PARPi treatment outcomes, offering a valuable tool for identifying patients who may benefit from PARPi therapy in ovarian cancer. However, the model needs further validation.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 9","pages":"101987"},"PeriodicalIF":4.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}